ArticlePediatrics2019
CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections.
Article in Pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Clinical pharmacology and therapeutics · 2021Guideline
- Utility of theClinical and translational science · 2022Trial
- Infant Acid-Suppressant Medication, C. difficile Colonisation, and Childhood Body Mass Index in a Canadian Cohort.Acta paediatrica (Oslo, Norway : 1992) · 2025Article
- Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker.Advances in therapy · 2025Article
- Association betweenFrontiers in pharmacology · 2025Review
- Effect of MDR1 C3435T and CYP2C19 genetic polymorphisms on the outcome of Helicobacter pylori eradication treatment in children with gastritis and peptic ulcer, Vietnam.BMC pediatrics · 2024Article
- Evaluation ofPharmacogenomics and personalized medicine · 2024Article
- Vonoprazan-associatedTherapeutic advances in drug safety · 2024Article
- A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants.Paediatric drugs · 2023Review
- Pharmacogenetic Testing for the Pediatric Gastroenterologist: Actionable Drug-Gene Pairs to Know.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Advancing Precision Medicine in Paediatrics: Past, present and future.Cambridge prisms. Precision medicine · 2023Review
- A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps.Pharmacogenomics and personalized medicine · 2023Review
- Analysis of Neurodevelopment in Children Born Extremely Preterm Treated With Acid Suppressants Before Age 2 Years.JAMA network open · 2022Article
- Pharmacogenetic Expression of CYP2C19 in a Pediatric Population.Journal of personalized medicine · 2022Review
- Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians.Pediatric research · 2022Review
- Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.JAMA network open · 2021Article
- Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.Clinical and translational science · 2021Observational
- The impact of gastrointestinal dysmotility on the aerodigestive microbiome of pediatric lung transplant recipients.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2021Article
- Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.Clinical and translational science · 2021Article
- Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.International journal of molecular sciences · 2020Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
objectivesProton pump inhibitors (PPIs) are often used in pediatrics to treat common gastrointestinal disorders, and there are growing concerns for infectious adverse events. Because CYP2C19 inactivates PPIs, genetic variants that increase CYP2C19 function may decrease PPI exposure and infections. We tested the hypothesis that CYP2C19 metabolizer phenotypes are associated with infection event rates in children exposed to PPIs.
methodsThis retrospective biorepository cohort study included individuals aged 0 to 36 months at the time of PPI exposure. Respiratory tract and gastrointestinal tract infection events were identified by using
resultsIn all, 670 individuals were included (median age 7 months; 44% girls). CYP2C19 NMs (
conclusionsPPI therapy is associated with higher infection rates in children with normal CYP2C19 function than in those with increased CYP2C19 function, highlighting this adverse effect of PPI therapy and the relevance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.